1. Afdhal, N. H., & Nunes, D. (2004). Evaluation of liver fibrosis: A concise review. American Journal of Gastroenterology, 99(6), 1160–1174.
2. Ahn, S. B., Jun, D. W., Kang, B. K., Lim, J. H., Lim, S., & Chung, M. J. (2019). Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Scientific Reports, 9(1), 1–9.
3. Aragonès, G., González-García, S., Aguilar, C., Richart, C., & Auguet, T. (2019). Gut microbiota-derived mediators as potential markers in nonalcoholic fatty liver disease. BioMed Research International, 2019, 1–10.
4. Argamasilla, R., Roehring, C., & Koal, T. (2020). Metabolome and lipidome analysis of human fecal samples using the MxP® quant 500 kit. Application Note 35039 V2_02-2020. BIOCRATES Life Sciences AG, Innsbruck, Austria. Retrieved January 23, 2021 from https://biocrates.com/wp-content/uploads/2020/04/ApplicationNote_35039_Quant500_Feces_V2.pdf
5. Asociación Argentina para el Estudio de las Enfermedades del Hígado. (2019). Primer Guía de Diagnóstico y Tratamiento del Hígado Graso No Alcohólico de la Asociación Argentina para el Estudio de las Enfermedades del Hígado. Retrieved January 23, 2021 from https://www.aaeeh.org.ar/es/attachment/show/40